Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

Simple item page
dc.contributor.authorEmbi, Peter J.
dc.contributor.authorLevy, Matthew E.
dc.contributor.authorNaleway, Allison L.
dc.contributor.authorPatel, Palak
dc.contributor.authorGaglani, Manjusha
dc.contributor.authorNatarajan, Karthik
dc.contributor.authorDascomb, Kristin
dc.contributor.authorOng, Toan C.
dc.contributor.authorKlein, Nicola P.
dc.contributor.authorLiao, I-Chia
dc.contributor.authorGrannis, Shaun J.
dc.contributor.authorHan, Jungmi
dc.contributor.authorStenehjem, Edward
dc.contributor.authorDunne, Margaret M.
dc.contributor.authorLewis, Ned
dc.contributor.authorIrving, Stephanie A.
dc.contributor.authorRao, Suchitra
dc.contributor.authorMcEvoy, Charlene
dc.contributor.authorBozio, Catherine H.
dc.contributor.authorMurthy, Kempapura
dc.contributor.authorDixon, Brian E.
dc.contributor.authorGrisel, Nancy
dc.contributor.authorYang, Duck-Hye
dc.contributor.authorGoddard, Kristin
dc.contributor.authorKharbanda, Anupam B.
dc.contributor.authorReynolds, Sue
dc.contributor.authorRaiyani, Chandni
dc.contributor.authorFadel, William F.
dc.contributor.authorArndorfer, Julie
dc.contributor.authorRowley, Elizabeth A.
dc.contributor.authorFireman, Bruce
dc.contributor.authorFerdinands, Jill
dc.contributor.authorValvi, Nimish R.
dc.contributor.authorBall, Sarah W.
dc.contributor.authorZerbo, Ousseny
dc.contributor.authorGriggs, Eric P.
dc.contributor.authorMitchell, Patrick K.
dc.contributor.authorPorter, Rachael M.
dc.contributor.authorKiduko, Salome A.
dc.contributor.authorBlanton, Lenee
dc.contributor.authorZhuang, Yan
dc.contributor.authorSteffens, Andrea
dc.contributor.authorReese, Sarah E.
dc.contributor.authorOlson, Natalie
dc.contributor.authorWilliams, Jeremiah
dc.contributor.authorDickerson, Monica
dc.contributor.authorMcMorrow, Meredith
dc.contributor.authorSchrag, Stephanie J.
dc.contributor.authorVerani, Jennifer R.
dc.contributor.authorFry, Alicia M.
dc.contributor.authorAzziz-Baumgartner, Eduardo
dc.contributor.authorBarron, Michelle A.
dc.contributor.authorThompson, Mark G.
dc.contributor.authorDeSilva, Malini B.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2022-02-24T15:30:56Z
dc.date.available2022-02-24T15:30:56Z
dc.date.issued2021-11
dc.description.abstractWhat is already known about this topic? Studies suggest that immunocompromised persons who receive COVID-19 vaccination might not develop high neutralizing antibody titers or be as protected against severe COVID-19 outcomes as are immunocompetent persons. What is added by this report? Effectiveness of mRNA vaccination against laboratory-confirmed COVID-19–associated hospitalization was lower (77%) among immunocompromised adults than among immunocompetent adults (90%). Vaccine effectiveness varied considerably among immunocompromised patient subgroups. What are the implications for public health practice? Immunocompromised persons benefit from COVID-19 mRNA vaccination but are less protected from severe COVID-19 outcomes than are immunocompetent persons. Immunocompromised persons receiving mRNA COVID-19 vaccines should receive 3 doses and a booster, consistent with CDC recommendations, practice nonpharmaceutical interventions, and, if infected, be monitored closely and considered early for proven therapies that can prevent severe outcomes.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationEmbi, P. J., Levy, M. E., Naleway, A. L., Patel, P., Gaglani, M., Natarajan, K., Dascomb, K., Ong, T. C., Klein, N. P., Liao, I.-C., Grannis, S. J., Han, J., Stenehjem, E., Dunne, M. M., Lewis, N., Irving, S. A., Rao, S., McEvoy, C., Bozio, C. H., … DeSilva, M. B. (2021). Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults—Nine States, January–September 2021. MMWR. Morbidity and Mortality Weekly Report, 70(44), 1553–1559. https://doi.org/10.15585/mmwr.mm7044e3en_US
dc.identifier.issn0149-2195, 1545-861Xen_US
dc.identifier.urihttps://hdl.handle.net/1805/27935
dc.language.isoen_USen_US
dc.publisherCDCen_US
dc.relation.isversionof10.15585/mmwr.mm7044e3en_US
dc.relation.journalMMWR. Morbidity and Mortality Weekly Reporten_US
dc.rightsCC0 1.0 Universal (CC0 1.0)
dc.rights.urihttps://creativecommons.org/publicdomain/zero/1.0/
dc.sourcePublisheren_US
dc.subjectimmunocompromised personsen_US
dc.subjectCovid-19en_US
dc.subjectCOVID-19 vaccinationen_US
dc.subjectantibody titersen_US
dc.subjectmRNA vaccinationen_US
dc.titleEffectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Embi2021Effectiveness-PUBLICDOMAIN.pdf
Size:
145.93 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medicine Works
Open Access Coronavirus-Related Works